FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602086903> ?p ?o ?g. }

• W2602086903 endingPage "8526" @default.
• W2602086903 startingPage "8526" @default.
• W2602086903 abstract "8526 Background: PI3K-delta signaling is critical for activation, proliferation and survival of B cells, plays a role in homing and retention in lymphoid tissues, and is hyperactive in many B-cell malignancies. Idelalisib (GS-1101) is a first-in-class, selective, oral inhibitor of PI3Kδ. Initial response rate of 38% was reported previously in iNHL (Kahl, ICML 2011). Long-term follow-up is now presented. Methods: This phase 1 study evaluated the activity of continuous idelalisib monotherapy in pts with relapsed hematologic malignancies. Doses ranged from 50 to 350 mg QD or BID in 8 cohorts. Response was evaluated based on investigator assessments using standard criteria (Cheson, 2007). Pts who continued to benefit were able to enroll in an ongoing extension study. Results: Study enrolled 64 pts with indolent iNHL. iNHL subtypes included 38 FL, 11 SLL, 9 LPL/WM, and 6 MZL. Pts were 69% male, median age [range] of 64 [32E91] years, 58% with refractory disease and 53% with bulky disease (LN diameter ≥5 cm). The median [range] number of prior therapies was 4 [1E10]. The median [range] duration of treatment was 3.8 [0-41] months, with 19 (30%) pts continuing on treatment extension protocol. ORR across all cohorts were 31/64 (48%), with 1 CR (1.6%). The median duration of response (mDOR) was 18.4 months, and median PFS (mPFS) was 7.6 months. For pts dosed with ≥100 mg BID (N=36); the ORR was 24/36 (67%), the mDOR was 15.4 months, and the mPFS was 16.6 months. The ORR for iNHL subtypes was: FL (45%), SLL (64%), LPL/WM (56%), and MZL (33%). Adverse events included (total%/≥G3%) diarrhea (36/8), fatigue (36/3), rash (27/3), nausea (25/2), pyrexia (20/3), chills (20/0), cough (19/2), pneumonia (17/16), and URI (17/0). Lab abnormalities included (total%/≥G3%) ALT/AST elevations (56/25). 8/64 (12.5%) pts discontinued therapy due to potentially treatment-related adverse events. Conclusions: The oral PI3Kδ inhibitor idelalisib is active in heavily pretreated pts with iNHL, can produce durable responses, and has a favorable safety profile. These data support further clinical development; phase 2 and 3 trials in iNHL are ongoing (NCT01732913, NCT01732926). Clinical trial information: NCT00710528." @default.
• W2602086903 created "2017-04-07" @default.
• W2602086903 creator A5000921376 @default.
• W2602086903 creator A5000959540 @default.
• W2602086903 creator A5003766253 @default.
• W2602086903 creator A5007034768 @default.
• W2602086903 creator A5013974745 @default.
• W2602086903 creator A5015361329 @default.
• W2602086903 creator A5015491065 @default.
• W2602086903 creator A5016570475 @default.
• W2602086903 creator A5027453053 @default.
• W2602086903 creator A5037882455 @default.
• W2602086903 creator A5042317118 @default.
• W2602086903 creator A5048838398 @default.
• W2602086903 creator A5069054551 @default.
• W2602086903 creator A5073720570 @default.
• W2602086903 creator A5075675241 @default.
• W2602086903 date "2013-05-20" @default.
• W2602086903 modified "2023-10-07" @default.
• W2602086903 title "Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)." @default.
• W2602086903 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.8526" @default.
• W2602086903 hasPublicationYear "2013" @default.
• W2602086903 type Work @default.
• W2602086903 sameAs 2602086903 @default.
• W2602086903 citedByCount "9" @default.
• W2602086903 countsByYear W26020869032014 @default.
• W2602086903 countsByYear W26020869032015 @default.
• W2602086903 countsByYear W26020869032016 @default.
• W2602086903 countsByYear W26020869032019 @default.
• W2602086903 countsByYear W26020869032020 @default.
• W2602086903 crossrefType "journal-article" @default.
• W2602086903 hasAuthorship W2602086903A5000921376 @default.
• W2602086903 hasAuthorship W2602086903A5000959540 @default.
• W2602086903 hasAuthorship W2602086903A5003766253 @default.
• W2602086903 hasAuthorship W2602086903A5007034768 @default.
• W2602086903 hasAuthorship W2602086903A5013974745 @default.
• W2602086903 hasAuthorship W2602086903A5015361329 @default.
• W2602086903 hasAuthorship W2602086903A5015491065 @default.
• W2602086903 hasAuthorship W2602086903A5016570475 @default.
• W2602086903 hasAuthorship W2602086903A5027453053 @default.
• W2602086903 hasAuthorship W2602086903A5037882455 @default.
• W2602086903 hasAuthorship W2602086903A5042317118 @default.
• W2602086903 hasAuthorship W2602086903A5048838398 @default.
• W2602086903 hasAuthorship W2602086903A5069054551 @default.
• W2602086903 hasAuthorship W2602086903A5073720570 @default.
• W2602086903 hasAuthorship W2602086903A5075675241 @default.
• W2602086903 hasConcept C121332964 @default.
• W2602086903 hasConcept C126322002 @default.
• W2602086903 hasConcept C142424586 @default.
• W2602086903 hasConcept C143998085 @default.
• W2602086903 hasConcept C2777938653 @default.
• W2602086903 hasConcept C2778461978 @default.
• W2602086903 hasConcept C2779260929 @default.
• W2602086903 hasConcept C2779878957 @default.
• W2602086903 hasConcept C71924100 @default.
• W2602086903 hasConcept C87355193 @default.
• W2602086903 hasConcept C90924648 @default.
• W2602086903 hasConceptScore W2602086903C121332964 @default.
• W2602086903 hasConceptScore W2602086903C126322002 @default.
• W2602086903 hasConceptScore W2602086903C142424586 @default.
• W2602086903 hasConceptScore W2602086903C143998085 @default.
• W2602086903 hasConceptScore W2602086903C2777938653 @default.
• W2602086903 hasConceptScore W2602086903C2778461978 @default.
• W2602086903 hasConceptScore W2602086903C2779260929 @default.
• W2602086903 hasConceptScore W2602086903C2779878957 @default.
• W2602086903 hasConceptScore W2602086903C71924100 @default.
• W2602086903 hasConceptScore W2602086903C87355193 @default.
• W2602086903 hasConceptScore W2602086903C90924648 @default.
• W2602086903 hasIssue "15_suppl" @default.
• W2602086903 hasLocation W26020869031 @default.
• W2602086903 hasOpenAccess W2602086903 @default.
• W2602086903 hasPrimaryLocation W26020869031 @default.
• W2602086903 hasRelatedWork W2068316626 @default.
• W2602086903 hasRelatedWork W2110818089 @default.
• W2602086903 hasRelatedWork W2351796763 @default.
• W2602086903 hasRelatedWork W2351985199 @default.
• W2602086903 hasRelatedWork W2403502999 @default.
• W2602086903 hasRelatedWork W2528057197 @default.
• W2602086903 hasRelatedWork W2567738959 @default.
• W2602086903 hasRelatedWork W2789412726 @default.
• W2602086903 hasRelatedWork W4297834875 @default.
• W2602086903 hasRelatedWork W4366141624 @default.
• W2602086903 hasVolume "31" @default.
• W2602086903 isParatext "false" @default.
• W2602086903 isRetracted "false" @default.
• W2602086903 magId "2602086903" @default.
• W2602086903 workType "article" @default.